You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PDL1 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With

Not yet recruiting
  • Gastric Cancer
  • Observational
  • (no location specified)
Dec 13, 2022

Solid Tumor Malignancy, Hematologic Malignancy, Leukemia Trial run by the NCI (mrna 1273 injection)

Recruiting
  • Solid Tumor Malignancy
  • +4 more
  • mRNA-1273
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 14, 2023

Sarcoma,Soft Tissue Trial in France (Cobimetinib, Atezolizumab)

Recruiting
  • Sarcoma,Soft Tissue
  • Angers, France
  • +4 more
Mar 28, 2022

Liver Cancer Trial in Guanzhou (PD1/PDL1 inhibitor)

Unknown status
  • Liver Cancer
  • PD1/PDL1 inhibitor
  • Guanzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Apr 4, 2021

NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Phase I - Mirdametinib - Level 1
  • +4 more
  • (no location specified)
Jul 7, 2023

Non-Squamous NSCLC (NSCLC), Adenocarcinoma of the Lung, Lung Cancer Trial in United States (Docetaxel, Nivolumab, Gemcitabine)

Terminated
Has Results
  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • +3 more
  • Anderson, Indiana
  • +8 more
Jul 7, 2022

Head/Neck Tumor Trial in Guanzhou (PD1/PDL1 inhibitor)

Recruiting
  • Head/Neck Neoplasm
  • PD1/PDL1 inhibitor
  • Guanzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Apr 4, 2021

Melanoma, Non Small Cell Lung Cancer, Renal Cancer Trial in Clermont-Ferrand (Blood sample)

Recruiting
  • Melanoma
  • +2 more
  • Blood sample
  • Clermont-Ferrand, France
    CHU de Clermont-Ferrand
Jun 16, 2022

Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer Trial in Lyon, Toulouse (Pexidartinib, Durvalumab)

Completed
  • Colorectal Cancer
  • +3 more
  • Lyon, France
  • +1 more
Sep 2, 2021

Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (Atezolizumab,

Active, not recruiting
  • Breast Adenocarcinoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 6, 2021

PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact

Not yet recruiting
  • PDL1- Colorectal Carcinoma
    • (no location specified)
    Jan 11, 2023

    Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT

    Recruiting
    • Lung Cancer Stage III
    • Lung Cancer Stage IV
      • Brest, France
        Chu Brest
      Aug 16, 2023

      Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France

      Not yet recruiting
      • Metastatic Renal Cell Carcinoma
      • Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
      • Combination PD-1/PD-L1 ICI + VEGFR-TKI
      • Treatment pause
      • Bayonne, France
      • +24 more
      Aug 10, 2022

      Metastatic Renal Cell Carcinoma Trial in Milan (Cabometyx)

      Completed
      • Metastatic Renal Cell Carcinoma
      • Milan, Italy
        Fondazione IRCCS Istituto Nazionale Tumori
      Apr 23, 2021

      Metastatic Solid Tumors Trial in Canada, United States (M6223, Bintrafusp alfa)

      Recruiting
      • Metastatic Solid Tumors
      • Nashville, Tennessee
      • +3 more
      Oct 14, 2021

      Skin Health and Quality of Life in Patients Receiving

      Not yet recruiting
      • Lung Cancer
      • +7 more
      • EQ-5D-5L questionnaire
      • +2 more
      • Roma, Italy
        Roberto Iacovelli
      May 17, 2023

      Multiple Myeloma Trial (Bone marow biopsy and aspiration, biochemical and heamatological tests)

      Not yet recruiting
      • Multiple Myeloma
      • Bone marow biopsy and aspiration
      • biochemical and heamatological tests
      • (no location specified)
      Aug 9, 2023

      Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

      Active, not recruiting
      • Recurrent Acute Myeloid Leukemia
      • Refractory Acute Myeloid Leukemia
      • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
      • +6 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 25, 2022

      Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III

      Terminated
      • Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
      • +9 more
      • Bintrafusp Alfa
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Mar 4, 2022

      NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • +4 more
      • MK-2870
      • +2 more
      • (no location specified)
      Sep 15, 2023

      Advanced Tumors, Lymphoma, Metastatic Tumors Trial in Changchun, Jinan (HLX301)

      Recruiting
      • Advanced Tumors
      • +2 more
      • Changchun, Jilin, China
      • +1 more
      Jul 12, 2022

      PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

      Recruiting
      • Non-small Cell Lung Cancer
      • Monza, Italy
        ASST-Monza Ospedale San Gerardo
      Jun 9, 2022

      Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

      Not yet recruiting
      • Cervical Cancer
      • Recombinant humanized anti-PD-1 monoclonal antibody injection
      • +4 more
      • Wuhan, Hubei, China
        Tongji Hospital affiliated to Tongji Medical College of Huazhong
      Nov 3, 2023

      Circulating Tumor Cells in Non-small Cell Lung Cancer

      Recruiting
      • Lung Cancer
      • blood sample collection for CTC and MDSC analysis
      • Toulouse, France
        Larrey Hospital
      Nov 18, 2020

      SOX2 & PDL1 Expression on Urinary Bladder Carcinoma

      Not yet recruiting
      • Urinary Bladder Neoplasm
        • (no location specified)
        Jun 17, 2022